Our mission to help you navigate the new normal is fueled by subscribers. To enjoy unlimited access to our journalism, subscribe today.
China has been vaccinating key workers against COVID-19 since July 22, the country’s National Health Commission (NHC) revealed on Saturday. The NHC didn’t say which of the four Chinese vaccines currently in the final phase of clinical trials had been used, but claimed that, so far, there had been no adverse effects.
According to NHC director Zheng Zhongwei, immigration officials and medical staff are among the groups that have received the vaccine as “most cases in China now are imported, so border officials are a high-risk group.”
China has gone eight days with zero cases of local transmission as of Monday. The most recent major clusters of COVID-19—as well as the initial coronavirus outbreak in December—have been traced to wet markets, where consumers gather to buy fresh meat and vegetables.
Subscribe to Eastworld for weekly insight on what’s dominating business in Asia, delivered free to your inbox.
The government intends to extend emergency vaccinations to workers in the markets as well as people in the transport and service industries to create an “immunity barrier.”
“We’ve drawn up a series of plan packages, including medical consent forms, side-effects monitoring plans, rescuing plans, compensation plans, to make sure the emergency use is well regulated and monitored,” Zheng told state broadcaster CCTV.
Rushing a vaccine past the final stage of testing is risky. New vaccines require the close monitoring of tens of thousands of test subjects in order to detect rare side-effects and to measure the vaccine’s effectiveness. But China is eager to prove it has the virus under control. Successful management of the disease and the development of an effective vaccine could offset accusations from Washington that Beijing is responsible for unleashing COVID-19.
Zheng didn’t say how many workers had received vaccinations nor how many more would, but the government is eager to increase immunity before winter, as it anticipates a possible resurgence of the virus in the cold months. Workers at some state-owned firms—particularly those who need to travel overseas—have been issued vaccines, too.
China’s military, the People’s Liberation Army (PLA), has also begun distributing vaccines to its personnel. China’s Central Military Commission gave the go ahead in June to vaccinate soldiers with a jab developed by CanSino Biologics in partnership with the Academy of Military Medical Sciences. The vaccine had just completed Phase II trials when it was approved for military use.
The secrecy of China’s vaccine campaign hasn’t sat well with some foreign governments, however. Last week, Papua New Guinea denied entry to Chinese workers bound for a mine run by state-owned Metallurgical Corporation of China (MCC) after learning the staff had received unapproved vaccines.
“The government of Papua New Guniea demands and deserves to fully understand vaccine development and SARS-CoV-2 vaccine immunisation program undertaken in China and its potential risks,” David Manning, Papua New Guinea’s head of disaster management, said.
More must-read international coverage from Fortune:
- Masks, small classes, and outdoor lessons: How 5 countries in Europe are reopening schools
- The U.S. wanted to starve Huawei of chips. It’s working
- It would cost $1 trillion to move global supply chains out of China—but the long-term gains could be worth it
- Amazon punished sellers for price gouging during lockdown. Germany is checking if that was legal
- Want to find the next $10-billion-plus takeover target? Watch executive stock sales carefully